載入中
NeurAxis, Inc. (NRXS) is an American company specializing in neuromodulation therapy devices. Its primary offering is IB-Stim, a percutaneous electrical nerve field stimulation system engineered to alleviate functional abdominal pain associated with irritable bowel syndrome in patients aged 11 to 18. NeurAxis markets its solutions to healthcare providers, predominantly hospitals and clinics. The firm, headquartered in Carmel, Indiana, was established in 2011 and operated as Innovative Health Solutions, Inc. until its rebranding to NeurAxis, Inc. in March 2022.
一般交易時段
US$6.66
−US$0.27 · -3.90%
盤中時間採用ET。市場資料可能有所延遲。
NeurAxis, Inc. (NRXS) is an American company specializing in neuromodulation therapy devices. Its primary offering is IB-Stim, a percutaneous electrical nerve field stimulation system engineered to alleviate functional abdominal pain associated with irritable bowel syndrome in patients aged 11 to 18. NeurAxis markets its solutions to healthcare providers, predominantly hospitals and clinics. The firm, headquartered in Carmel, Indiana, was established in 2011 and operated as Innovative Health Solutions, Inc. until its rebranding to NeurAxis, Inc. in March 2022.
日內區間
目前US$6.66
52週區間
目前US$6.66
盤中時間採用ET。市場資料可能有所延遲。
NeurAxis, Inc. (NRXS) is an American company specializing in neuromodulation therapy devices. Its primary offering is IB-Stim, a percutaneous electrical nerve field stimulation system engineered to alleviate functional abdominal pain associated with irritable bowel syndrome in patients aged 11 to 18. NeurAxis markets its solutions to healthcare providers, predominantly hospitals and clinics. The firm, headquartered in Carmel, Indiana, was established in 2011 and operated as Innovative Health Solutions, Inc. until its rebranding to NeurAxis, Inc. in March 2022.
日內區間
目前US$6.66
52週區間
目前US$6.66
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 356.93萬 USD | 268.59萬 USD | 246萬 USD | 268.47萬 USD | 272.13萬 USD |
| 銷貨成本 | 56.29萬 USD | 36.2萬 USD | 30.33萬 USD | 29.71萬 USD | 46.77萬 USD |
| 毛利 | 300.64萬 USD | 232.39萬 USD | 215.67萬 USD | 238.77萬 USD | 225.36萬 USD |
| 研究與開發 | 49.36萬 USD | 20.61萬 USD | 16.93萬 USD | 22.56萬 USD | 20.34萬 USD |
| 銷售、一般及管理費用 | 1034.27萬 USD | 927.46萬 USD | 865.19萬 USD | 553.43萬 USD | 502.03萬 USD |
| 營業費用 | 1083.63萬 USD | 948.07萬 USD | 882.12萬 USD | 575.99萬 USD | 522.37萬 USD |
| 利息收入 | — | — | −2772 USD | −232.22萬 USD | — |
| 利息支出 | 7.4萬 USD | 30.07萬 USD | 535.8萬 USD | 41.76萬 USD | 3.69萬 USD |
| 折舊和攤銷 | 5.95萬 USD | 3.78萬 USD | 4.07萬 USD | 3.71萬 USD | 3.67萬 USD |
| 營業利益 | −782.99萬 USD | −715.68萬 USD | −666.45萬 USD | −337.22萬 USD | −297萬 USD |
| 淨利 | −780.06萬 USD | −824.15萬 USD | −1462.67萬 USD | −478.01萬 USD | −302.8萬 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$8.00
上漲空間 20.12%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI133.94萬0.00%2.3兆 USD0.03%US$381.68-0.07%
Vanguard Extended Market ETFVXF65.84萬0.00%954億 USD0.05%US$234.27-0.31%
iShares Micro-Cap ETFIWC21.21萬0.02%13.17億 USD0.60%US$182.3-0.39%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM12萬0.10%1.17億 USD0.73%US$15.86-0.50%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
